Introduction
In vitro and in vivo experiments have demonstrated a potent yet opposite effect of IL-2 on both regulatory T cells (T REG ) and IL-17+CD45RA-CD4+ T cells (Th17). T REG cells have been implicated as an important immunoregulator enhancing tumor growth whereas Th17 cells may mediate tumor destruction. This study compares the effect of high-dose IL-2 (HDIL-2) on both the TREG and Th17 compartments in responders and non-responders.
Methods
Peripheral blood was collected at baseline and at 24, 48, 72, and 96 hours post-treatment from 6 patients undergoing HDIL-2 therapy under an IRB approved protocol. No patients enrolled received anti-PD-1 or anti-CTLA4 therapies. PBMCs were isolated and underwent intracellular cytokine and extracellular receptor staining for flow cytometry. Statistical analysis was performed using paired student's t tests via Prism 6.0e software.
Results
5 of 6 patients clinically progressed on HDIL-2 therapy (non-responders, NR), and these patients demonstrated an increase in the frequency of CD25+FoxP3+CD4+ T cells (T REG ) on day 4 of treatment (4% +/-1% on day 0 to 14% +/-6% on day 4, p value = 0.06). A single patient responded to HDIL-2 therapy (complete responder, CR) and demonstrated a decrease in the frequency of T REG cells on day 4 of treatment (9% on day 0 to 7% on day 4). HDIL-2 increased the frequency of IL-17 +CD45RA-CD4+ T cells (Th17) on day 4 of therapy in all patients analyzed (0.7% +/-0.4% on day 0 versus 2% +/-1% on day 4, p value=0.04; Figure 1 ). Absolute numbers of Th17 cells also demonstrated a statistically significant increase on day 4 of therapy (5 +/-1 cell/µL on day 0 versus 38 +/-24 cells/µL on day 4, p value=0.04, Figure 2) . Subsequent analyses demonstrated a negative Th17:T REG ratio on day 4 of HDIL-2 treatment in all non-responders. Importantly, the complete responder demonstrated a positive Th17:T REG ratio on day 4 of treatment ( Figure 3 ). The observed difference in cytokine production appeared to be specific to IL-17 as there was no statistically significant change in frequency or total numbers of IFN-g+ or IL-2+CD4+ and CD8+ T cells.
Conclusion
Our results suggest a distinct immunophenotype indicative of response to HDIL-2. Analysis of peripheral T REG and Th17 cell frequencies early in the course of HDIL-2 1 Department of General Surgery, Emory University, Atlanta, GA, USA Full list of author information is available at the end of the article Figure 1 Diller et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P297 http://www.immunotherapyofcancer.org/content/3/S2/P297 therapy may help identify those patients who would benefit from subsequent cycles. 
